Skip to content

Depreciation at other companies

Gilead Sciences logo
Gilead SciencesGILD
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%
Enterprise value$4.43B+2,204%
P/S79.9×+74.4×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's depreciation?
Tango Therapeutics (TNGX) reported depreciation of $463K in Q1 2026.
How has Tango Therapeutics's depreciation changed year-over-year?
Tango Therapeutics's depreciation decreased by 25.6% year-over-year, from $622K to $463K.
What is the long-term trend for Tango Therapeutics's depreciation?
Over 4 years (2021 to 2025), Tango Therapeutics's depreciation has grown at a 27.2% compound annual growth rate (CAGR), from $872K to $2.28M.